Format

Send to

Choose Destination
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00021. Epub 2019 Jun 3.

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.

Author information

1
Memorial Sloan Kettering Cancer Center, New York, NY.
2
Loxo Oncology, Stamford, CT.
3
New York University Langone Medical Center, New York, NY.
4
Weill Cornell Medical College, New York, NY.

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/authorcenter. S. Michael Rothenberg Employment: Loxo Stock and Other Ownership Interests: Loxo Dahlia Henry Employment: Loxo Stock and Other Ownership Interests: Loxo, Allergan, Axovant Sciences,Palatin Technologies Mark G. Kris Consulting or Advisory Role: AstraZeneca, Regeneron, Pfizer Travel, Accommodations, Expenses: AstraZeneca, Genentech Other Relationship: Memorial Sloan Kettering Cancer Center Robert J. Young Stock and Other Ownership Interests: Agios, Alexion Pharmaceuticals,Biogen, Celgene, Gilead Sciences, Karyopharm Therapeutics, Spark Therapeutics, Regeneron, Stemline Therapeutics, Vertex Consulting or Advisory Role: Agios, Puma Biotechnology, NordicNeuroLab, ICON Clinical Research Research Funding: Agios (Inst) David M. Hyman Consulting or Advisory Role: Atara Biotherapeutics, Chugai Pharma,CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Genentech Research Funding: AstraZeneca, Puma Biotechnology, Loxo Travel, Accommodations, Expenses: Genentech, Chugai Pharma Alexander Drilon Honoraria: Medscape, OncLive, PeerVoice, Physicians’ Education Resource, Targeted Oncology, MORE Health, Research to Practice, Foundation Medicine, PeerView Consulting or Advisory Role: Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche/Foundation Medicine, Helsinn Therapeutics, BeiGene, Hengrui Therapeutics, Exelixis, Bayer, Tyra Biosciences, Verastem, Takeda/Ariad/Millenium, BerGenBio, MORE Health Patents, Royalties, Other Intellectual Property: Wolters Kluwer (royalties for Pocket Oncology) Other Relationship: Merck, GlaxoSmithKline, Teva, Taiho Pharmaceutical No other potential conflicts of interest were reported.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center